Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672433 | 0.86 | CTDSP1 (0.46) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL15728078 | 0.82 | PKM (0.43) | SMN1; SMN2PKMALDH1A1KDM4EHSD17B10 | |
| SCHEMBL3160745 | 0.81 | CYP4F2 (0.55) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL17130343 | 0.81 | PKM (0.42) | SMN1; SMN2PKMALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5791048 | 0.80 | CYP3A4 (0.45) | SMN1; SMN2PKMALDH1A1KDM4EHSD17B10 | |
| SCHEMBL21060539 | 0.78 | MEN1 (0.42) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL29562190 | 0.78 | MEN1 (0.42) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL8549717 | 0.78 | PKM (0.43) | SMN1; SMN2PKMALDH1A1KDM4EHSD17B10 | |
| Bromide SCHEMBL7401891 | 0.78 | ERAP1 (0.48) | SMN1; SMN2PKMALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31070228 | 0.75 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | GLS, GLS2, GLUL | SMN1; SMN2 4347/4885PKM 487/4885ALDH1A1 552/4885 |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | SMN1; SMN2 4347/4885PKM 487/4885ALDH1A1 552/4885 |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | SMN1; SMN2 4347/4885PKM 487/4885ALDH1A1 552/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | SMN1; SMN2 4454/4885PKM 554/4885ALDH1A1 263/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | SMN1; SMN2 1335/4885PKM 3816/4885ALDH1A1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.